Several brokerages have updated their recommendations and price targets on shares of Aerie Pharmaceuticals (NASDAQ: AERI) in the last few weeks:

  • 8/8/2017 – Aerie Pharmaceuticals was given a new $65.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 8/2/2017 – Aerie Pharmaceuticals was given a new $69.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/1/2017 – Aerie Pharmaceuticals was given a new $65.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/28/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $70.00 price target on the stock.
  • 7/24/2017 – Aerie Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $66.00 price target on the stock. According to Zacks, “Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. Aerie had earlier withdrawn its NDA that was filed in September as a third party manufacturing facility in Tampa, FL was not ready for pre-approval inspection by the FDA. A potential approval and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. The recent data on Roclatan is also positive. Moreover, Aerie’s shares have outperformed the industry in the year so far. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa.”
  • 7/24/2017 – Aerie Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 7/20/2017 – Aerie Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $62.00 price target on the stock, up previously from $56.00.
  • 7/11/2017 – Aerie Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. Aerie had earlier withdrawn its NDA that was filed in September as a third party manufacturing facility in Tampa, FL was not ready for pre-approval inspection by the FDA. A potential approval and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. The recent data on Roclatan is also positive. Moreover, Aerie’s shares have outperformed the industry in the last 12 monts. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa.”
  • 7/4/2017 – Aerie Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $55.00 to $65.00. They now have a “buy” rating on the stock.
  • 7/3/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $65.00 price target on the stock.
  • 6/17/2017 – Aerie Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) traded down 0.38% during midday trading on Wednesday, reaching $52.20. The company had a trading volume of 593,504 shares. Aerie Pharmaceuticals, Inc. has a 1-year low of $17.84 and a 1-year high of $59.50. The stock’s market capitalization is $1.90 billion. The firm’s 50 day moving average is $54.36 and its 200 day moving average is $48.22.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.02. On average, equities analysts anticipate that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current fiscal year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 9.36% of the company’s stock.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.